E.S. Gershtein - Dr.Sc. (Biol.), Professor, N.N. Blokhin Russian Cancer Research Center (Moscow) E.R. Isaeva - Post-graduate Student, N.N. Blokhin Russian Cancer Research Center (Moscow) D.N. Kushlinsky - Surgeon oncogynecologist, Scientific Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov (Moscow) E.A. Korotkova - Ph.D. (Biol.), Senior Research Scientist, N.N. Blokhin Russian Cancer Research Center (Moscow) V.D. Ermilova - Ph.D. (Med.), Leading Research Scientist, anatomical pathologist, N.N. Blokhin Russian Cancer Research Center (Moscow) K.P. Laktionov - Dr.Sc. (Med.), Professor, N.N. Blokhin Russian Cancer Research Center (Moscow) L.V. Adamyan - Dr.Sc. (Med.), Professor, Scientific Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov (Moscow)

IGF-I, II, IGFBP-1, 2 and 3 levels were measured with standard ELISA kits (Mediagnost) in blood serum of 44 ovarian cancer, 12 benign and 11 borderline ovarian tumor patients. Control group comprised 33 practically healthy women.Serum IGF-1 content in ovarian cancer patients was significantly lower, and IGFBP-1 content - higher than in all other groups. IGFBP-2 level was increased both in ovarian cancer and borderline tumor groups as compared to control and benign ovarian tumor patients. No significant associations were found between the majority of parameters studied and main clinico-pathologic characteristics of ovarian cancer. Thus, disturbances in IGFs/IGBPs balance were revealed in blood serum of ovarian cancer patients, and IGFBP-2 proved to be a potential diagnostic serological marker with 90 % specificity and 90 % sensitivity.

 

1. Korolenkova L.I., Kushlinskijj D.N., Gershtejjn E.S., Ermilova V.D., Dvorova E.K.Insulinopodobnye faktory rosta syvorotki krovi bolnykh cervikalnojj intraehpitelialnojj giperplaziejj i invazivnym rakom shejjki matki kak perspektivnye markery progressii zabolevanija // Voprosy biologicheskojj, medicinskojj i farmacevticheskojj khimii. 2012. № 10. S. 21-35.
2. Masljaev A.V., Kostyleva O.I., Gershtejjn E.S., Ermilova V.D., Grickevich M.V., Portnojj S.M. Insulinopodobnye faktory rosta v syvorotke krovi bolnykh rakom molochnojj zhelezy // Voprosy biologicheskojj, medicinskojj i farmacevticheskojj khimii. 2012. № 10. S. 16-20.
3. Baron-Hay S., Boyle F., Ferrier A., Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer // Clin. Cancer Res. 2004. V. 10. № 5. P. 1796-1806.
4. Beauchamp M.C., Yasmeen A., Knafo A., Gotlieb W.H. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer // J. Oncol. 2010. V. 2010. P. 257058.
5. Brokaw J., Katsaros D., Wiley A. et al. IGF-I in epithelial ovarian cancer and its role in disease progression // Growth Factors. 2007. V. 25. № 5. P. 346-354.
6. Bruchim I., Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies // Expert. Opin. Ther. Targets. 2013. V. 17. № 3. P. 307-320.
7. Druckmann R., Rohr U.D. IGF-1 in gynaecology and obstetrics: update 2002 // Maturitas. 2002. V. 41. Suppl. 1. P. 65-83.
8. Huang G.S., Brouwer-Visser J., Ramirez M.J. et al.Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer // Clin. Cancer Res. 2010. V. 16. № 11. P. 2999-3010.
9. Katsaros D., Yu H., Levesque M.A. et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival // Eur. J. Cancer. 2001. V. 37. № 4. P. 478-485.
10. Peeters P.H., Lukanova A., Allen N. et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC) // Endocr. Relat. Cancer. 2007. V. 14. № 1. P. 81-90.
11. Sayer R.A., Lancaster J.M., Pittman J. et al. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer // Gynecol. Oncol. 2005. V. 96. № 2. P. 355-361.
12. Spentzos D., Cannistra S.A., Grall F. et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer // Endocr. Relat. Cancer. 2007. V. 14. № 3. P. 781-790.
13. Tworoger S.S., Lee I.M., Buring J.E. et al. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts // Cancer Epidemiol. Biomarkers Prev. 2007. V. 16. № 8. P. 1691-1695.
14. Waksmanski B., Dudkiewicz J., Kowalski T. Changes in insulin-like growth factor I, 17-b-estradiol, and progesterone in postmenopausal women with benign and malignant ovarian tumours // Med. Sci. Monit. 2001. V. 7. № 5. P. 919-923.
15. Westin S.N., Herzog T.J., Coleman R.L.Investigational agents in development for the treatment of ovarian cancer // Invest. New Drugs. 2012. V. 31. № 1. P. 213-229.